MX2022012062A - Receptores de linfocitos t. - Google Patents

Receptores de linfocitos t.

Info

Publication number
MX2022012062A
MX2022012062A MX2022012062A MX2022012062A MX2022012062A MX 2022012062 A MX2022012062 A MX 2022012062A MX 2022012062 A MX2022012062 A MX 2022012062A MX 2022012062 A MX2022012062 A MX 2022012062A MX 2022012062 A MX2022012062 A MX 2022012062A
Authority
MX
Mexico
Prior art keywords
lymphocyte receptors
receptors
lymphocyte
polynucleotides
polypeptides
Prior art date
Application number
MX2022012062A
Other languages
English (en)
Spanish (es)
Inventor
Jasdeep Mann
Original Assignee
2Seventy Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 2Seventy Bio Inc filed Critical 2Seventy Bio Inc
Publication of MX2022012062A publication Critical patent/MX2022012062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022012062A 2020-03-27 2021-03-26 Receptores de linfocitos t. MX2022012062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000800P 2020-03-27 2020-03-27
PCT/US2021/024370 WO2021195503A1 (en) 2020-03-27 2021-03-26 T cell receptors

Publications (1)

Publication Number Publication Date
MX2022012062A true MX2022012062A (es) 2023-01-11

Family

ID=77890524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012062A MX2022012062A (es) 2020-03-27 2021-03-26 Receptores de linfocitos t.

Country Status (11)

Country Link
US (1) US20230124640A1 (https=)
EP (1) EP4126924A4 (https=)
JP (2) JP7738007B2 (https=)
KR (1) KR20220160040A (https=)
CN (1) CN115485294A (https=)
AU (1) AU2021244594A1 (https=)
BR (1) BR112022019380A2 (https=)
CA (1) CA3177181A1 (https=)
IL (1) IL296827A (https=)
MX (1) MX2022012062A (https=)
WO (1) WO2021195503A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
CN117003855B (zh) * 2023-09-20 2024-02-23 广州市老人院 一种t细胞受体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361794B2 (en) * 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
LT3424947T (lt) * 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
CN102876715B (zh) 2012-09-05 2014-07-23 南方医科大学 一种用于结核/hiv共感染基因治疗的逆转录病毒载体及其应用
CN102911267B (zh) 2012-09-19 2014-04-02 南方医科大学 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用
EP3472208B9 (en) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH T cell receptors and uses thereof
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
BR112020006643A2 (pt) * 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포
CA3225252A1 (en) * 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies

Also Published As

Publication number Publication date
KR20220160040A (ko) 2022-12-05
IL296827A (en) 2022-11-01
CN115485294A (zh) 2022-12-16
CA3177181A1 (en) 2021-09-30
BR112022019380A2 (pt) 2022-11-29
JP2025172113A (ja) 2025-11-20
EP4126924A1 (en) 2023-02-08
EP4126924A4 (en) 2024-04-24
JP7738007B2 (ja) 2025-09-11
JP2023519868A (ja) 2023-05-15
AU2021244594A1 (en) 2022-12-01
US20230124640A1 (en) 2023-04-20
WO2021195503A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2021015452A (es) Proteinas de fusion flt3l-fc y metodos de uso.
MX2022012062A (es) Receptores de linfocitos t.
BR112021017113A2 (pt) Receptores de citocinas quiméricos portadores de um ectodomínio de pd-1
CL2021001153A1 (es) Receptores de antígenos quiméricos específicos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteína g (gprc5d)
EA202092945A1 (ru) Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии
MX2022001018A (es) Electrodos metalicos de bajo costo.
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
MY206523A (en) Constitutively active chimeric cytokine receptors
MX2020009774A (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
EA201892137A1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA202092243A1 (ru) Способы усиления персистенции адоптивно инфузированных т-клеток
MX2021011462A (es) Receptores de linfocitos t y metodos de uso de los mismos.
MX421741B (es) Inmunoterapia con receptores de antígeno quimérico y uso de la misma
MX2021009722A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
MX2022000367A (es) Heterodimeros, metodos y uso de los mismos.
CL2022001541A1 (es) Anticuerpos anti-ly6g6d y métodos de uso.
WO2018120843A9 (zh) 一种三功能分子及其应用
MX2016005687A (es) Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta.
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
EA201892588A1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
BR112022003852A2 (pt) Métodos de preparação de células t para terapia de células t
CL2024001654A1 (es) Anticuerpos antimutantes de calreticulina (calr) y usos de los mismos.
AR112602A1 (es) ANTICUERPOS ANTI-TrkB
CL2024000180A1 (es) Composiciones y métodos para tratar la endometriosis.